Promising drug trial for thyroid eye disease halted early

NCT ID NCT04737330

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called secukinumab in adults with active, moderate to severe thyroid eye disease, a condition that causes bulging eyes and discomfort. The trial aimed to see if the drug could reduce eye bulging and inflammation. However, the study was stopped early and only 28 people took part, so the results are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secukinumab
What this could lead to: If this treatment had worked, it could have pointed toward a new option for controlling thyroid eye disease without surgery.
What could go wrong: The trial was stopped early with only 28 participants, so we have very little data. It is unclear if secukinumab is effective or safe for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES ORBITOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAVES ORBITOPATHY THYROID EYE DISEASE

Contacts and locations

Locations

Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Frankfurt, 60318, Germany
Novartis Investigative Site

Freiburg im Breisgau, 79106, Germany
Novartis Investigative Site

Göttingen, 37075, Germany
Novartis Investigative Site

Mainz, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.